deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT01249443

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

A Phase 1 Study of Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection

Sponsor: AIDS Malignancy Consortium

Conditions HIV Infection Recurrent Anal Cancer Recurrent Breast Cancer Recurrent Esophageal Cancer Recurrent Gastric Cancer Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Non-small Cell Lung Cancer Recurrent Ovarian Epithelial Cancer Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Salivary Gland Squamous Cell Carcinoma Stage IV Anal Cancer Stage IV Breast Cancer Stage IV Esophageal Cancer Stage IV Gastric Cancer Stage IV Non-small Cell Lung Cancer Stage IV Ovarian Epithelial Cancer Stage IV Salivary Gland Cancer Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Larynx Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IV Squamous Cell Carcinoma of the Oropharynx Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IV Verrucous Carcinoma of the Larynx Stage IV Verrucous Carcinoma of the Oral Cavity Unspecified Adult Solid Tumor, Protocol Specific
Interventions carboplatin diagnostic laboratory biomarker analysis paclitaxel pharmacological study vorinostat
Updated 11 times since 2017 Last updated: Jul 28, 2020 Started: Nov 30, 2013 Primary completion: May 31, 2016 Completion: Dec 31, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Inadequate accrual rate

Other terminated trials from AIDS Malignancy Consortium

See all terminations from AIDS Malignancy Consortium

Other HIV Infection trials with similar outcome

Browse all HIV Infection trials

This PHASE1 trial investigates HIV Infection and Recurrent Anal Cancer and is currently terminated or withdrawn. AIDS Malignancy Consortium leads this study, which shows 11 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshotActive Not Recruiting~Sep 2017 – ~Jan 2018 · 4 months · monthly snapshotTerminated~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshotTerminated~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshotTerminated~Jun 2019 – ~Aug 2020 · 14 months · monthly snapshotTerminated~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  5. Aug 2020 — Jan 2021 [monthly]

    Terminated PHASE1

▶ Show 6 earlier versions

  1. Jun 2019 — Aug 2020 [monthly]

    Terminated PHASE1

  2. Jun 2018 — Jun 2019 [monthly]

    Terminated PHASE1

  3. Jan 2018 — Jun 2018 [monthly]

    Terminated PHASE1

  4. Sep 2017 — Jan 2018 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  5. Feb 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AIDS Malignancy Consortium
  • National Cancer Institute (NCI)
  • The Emmes Company, LLC
  • University of Arkansas
Data source: AIDS Malignancy Consortium

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations